A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01928147
Recruitment Status : Completed
First Posted : August 23, 2013
Last Update Posted : November 26, 2015
Information provided by (Responsible Party):
Presidio Pharmaceuticals, Inc.

Brief Summary:
PPI-383 is an antiviral agent (an inhibitor of the hepatitis C virus NS5B polymerase) that is being developed as a potential treatment for hepatitis C virus infection. This study is being done to assess the dose-related safety and tolerance of PPI-383 when given to healthy volunteers for up to 5 days (Part I of the study) and to hepatitis C patients for up to 3 days (Part II). In addition, the study will assess how much PPI-383 is absorbed into the bloodstream. In Part II, the dose-related effect of PPI-383 on the amount of hepatitis C virus in patients' bloodstream (serum HCV RNA levels) also will be assessed.

Condition or disease Intervention/treatment Phase
Hepatitis C, Chronic Drug: PPI-383 Drug: Placebo Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 114 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase Ia and Ib Dose-Ranging Study to Assess the Safety, Pharmacokinetics, and Antiviral Efficacy of PPI-383 in Healthy Adults and Hepatitis C Patients
Study Start Date : August 2013
Actual Primary Completion Date : July 2015
Actual Study Completion Date : November 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: PPI-383 single dose escalation in healthy volunteers
There will be up to 10 sequential single dose cohorts to assess the bioavailability of different doses and formulations; a food effect cohort will be included.
Drug: PPI-383
Drug: Placebo
Experimental: PPI-383 multiple doses in healthy volunteers
Upon completion of the single dose cohorts, an additional cohort will receive the highest well-tolerated dose from the single dose cohorts or placebo once daily for five days; up to additional cohorts may receive multiple doses of different formulations or different regimens
Drug: PPI-383
Drug: Placebo
Experimental: PPI-383 multiple dose escalation in HCV Subjects
Upon completion of the single and multiple dose healthy volunteer cohorts, there will be 3, and potentially 4, sequential cohorts of HCV patients
Drug: PPI-383
Drug: Placebo

Primary Outcome Measures :
  1. Safety and tolerability, as measured by clinical adverse events and laboratory assessments [ Time Frame: Part I, up to day 12; and Part II, up to day 17 ]

Secondary Outcome Measures :
  1. PPI-383 plasma levels [ Time Frame: Part I, up to day 12; and Part II, up to day 17 ]
  2. serum HCV RNA levels [ Time Frame: Part II, up to day 17 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Part I volunteers (single and multiple dose) - key inclusion criteria

  • Healthy males
  • Age 18 to 55 years
  • Body mass index (BMI)18 to 32 kg/m2

Part II patients- key inclusion criteria

  • Males, or females of non-childbearing potential
  • Age 18 to 65 years
  • Chronic hepatitis C, and absence of other known liver disease
  • Seropositive for HCV antibody (HCV Ab) or HCV RNA at least once previously
  • Seropositive for HCV Ab at screening
  • Serum HCV RNA > 5 log10 IU/mL at screening
  • HCV gt-1
  • Treatment-naïve for hepatitis C:
  • BMI 18 to 35 kg/m2
  • Otherwise in good health, without severe or clinically significant chronic or recurrent conditions requiring frequent medical intervention or continual pharmacologic management, except for anti-hypertensive use
  • No medical or psychosocial conditions that would potentially interfere with the subject's ability to comply with the study assessments or visit schedule.

Part II patients - key exclusion criteria

  • Seropositive for human immunodeficiency virus (HIV) antibody or hepatitis B virus (HBV) surface antigen (HBsAg)
  • Signs or symptoms of decompensated liver disease
  • Evidence of cirrhosis or hepatocellular carcinoma
  • Diabetes Mellitus treated with insulin or hypoglycemic agents
  • Asthma requiring hospital admission within the preceding 12 months
  • History of alcohol abuse or illicit drug use which could interfere with a patient's compliance with the protocol requirements
  • Any of the following laboratory values at screening

    • Haemoglobin (Hgb) <11 g/dL in women or 12 g/dL in men
    • White blood cell count <4,000/mm3
    • Absolute neutrophil count (ANC) < 1800 per mm3
    • Platelet count <100,000 per mm3
    • Serum creatinine > upper limit of normal (ULN) at the central study laboratory
    • Serum albumin <3.4 g/dL
    • Total bilirubin >2.0 mg/dL
  • Clinically significant abnormality in the electrocardiograms (ECGs) at screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01928147

Investigational site
Phoenix, Mauritius
United Kingdom
Investigational site
London, United Kingdom, NW3 2QG
Investigational site
London, United Kingdom, SE5 9RS
Investigational site
London, United Kingdom, UE1 2AD
Investigational site
London, United Kingdom, W2 1NY
Investigational site
Nottingham, United Kingdom
Sponsors and Collaborators
Presidio Pharmaceuticals, Inc.
Study Director: Nathaniel Brown, M.D. Presidio Pharmaceuticals

Responsible Party: Presidio Pharmaceuticals, Inc. Identifier: NCT01928147     History of Changes
Other Study ID Numbers: PPI-383-101
First Posted: August 23, 2013    Key Record Dates
Last Update Posted: November 26, 2015
Last Verified: November 2015

Keywords provided by Presidio Pharmaceuticals, Inc.:
NS5B polymerase inhibitor
Phase 1
Genotype 1

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Hepatitis, Chronic